Surveillance of triazole susceptibility of colonizing yeasts in patients with haematological malignancies

Scandinavian Journal of Infectious Diseases

Volumn 36, Issue 11-12, 2004, Pages 855-859

  Chryssanthou, Erja ^a   Cherif, Honar ^a   Petrini, Björn ^a   Kalin, Mats ^a   Björkholm, Magnus ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA NORVEGENSIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CROSS RESISTANCE; DRUG SENSITIVITY; FEMALE; FUNGAL COLONIZATION; FUNGAL STRAIN; FUNGUS CULTURE; FUNGUS ISOLATION; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NONHUMAN; SACCHAROMYCES CEREVISIAE; SPECIES DISTRIBUTION; STATISTICAL ANALYSIS; YEAST;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; FEMALE; FUNGI; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOSES; NEUTROPENIA; TRIAZOLES;

EID: 11344274175     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540410021108     Document Type: Article

References (37)

1. Bow EJ. Invasive fungal infections in patients receiving intensive cytotoxic therapy for cancer. Br J Haematol 1998; 101(Suppl 1): 1-4.
2. Bow EJ. Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies. J Antimicrob Chemother 1998; 41(Suppl D): 1-5.
3. Fisher-Hoch SP, Hutwagner L. Opportunistic candidiasis: an epidemic of the 1980s. Clin Infect Dis 1995;,21: 897-904.
4. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungaemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989; 11: 379-90.
5. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidaemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15: 414-21.
6. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001; 150: 101-15.
7. Winston DJ, Ho WG, Champlin RE, Gale RP. Infectious complications of bone marrow transplantation. Exp Hematol 1984; 12: 205-15.
8. Horn R, Wong B, Kiehn TE, Armstrong D. Fungaemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis 1985; 7: 646-55.
9. Tortorano AM, Rigoni AL, Biraghi E, Prigitano A, Viviani MA. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J Antimicrob Chemother 2003; 52: 679-82.
10. Garbino J, Kolarova L, Rohner P, Lew D, Pichna P, Pittet D. Secular trends of candidaemia over 12 y in adult patients at a tertiary care hospital. Medicine (Baltimore) 2002; 81: 425-33.
11. Laverdiere M, Rotstein C, Bow EJ, Roberts RS, Ioannou S, Carr D, et al. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study. J Antimicrob Chemother 2000; 46: 1001-8.
12. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002; 94: 3230-46.
13. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28: 331-40.
14. Preston SL, Briceland LL. Fluconazole for antifungal prophylaxis in chemotherapy-induced neutropenia. Am J Health Syst Pharm 1995; 52: 164-73; quiz 205-6.
15. Kanda Y, Yamamoto R, Chizuka A, Hamaki T, Suguro M, Arai C, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000; 89: 1611-25.
16. Goldman M, Cloud GA, Smedema M, LeMonte A, Connolly P, McKinsey DS, et al. Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? The National Institute of Allergy and Infectious Diseases Mycoses study group. Antimicrob Agents Chemother 2000; 44: 1585-7.
17. Davies A, Brailsford S, Broadley K, Beighton D. Resistance amongst yeasts isolated from the oral cavities of patients with advanced cancer. Palliat Med 2002; 16: 527-31.
18. Chandrasekar PH, Gatny CM. The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Bone Marrow Transplantation Team. J Antimicrob Chemother 1994; 33: 309-18.
19. Fichtenbaum CJ, Koletar S, Yiannoutsos C, Holland F, Pottage J, Cohn SE, et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis 2000; 30: 749-56.
20. Bagg J, Sweeney MP, Lewis MA, Jackson MS, Coleman D, Al MA, et al. High prevalence of non-albicans yeasts and detection of anti-fungal resistance in the oral flora of patients with advanced cancer. Palliat Med 2003; 17: 477-81.
21. Sandven P, Nilsen K, Digranes A, Tjade T, Lassen J. Candida norvegensis: a fluconazole-resistant species. Antimicrob Agents Chemother 1997; 41: 1375-6.
22. Chryssanthou E, Cuenca-Estrella M. Comparison of the Anti-fungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol 2002; 40: 3841-4.
23. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard NCCLS document M27-A2. National Committee For Clinical Laboratory Standards, Wayne, Pa.
24. Powderly WG, Finkelstein D, Feinberg J, Frame P, He W, van der Horst C, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332: 700-5.
25. Schuman P, Capps L, Peng G, Vazquez J, el-Sadr W, Goldman AI, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med 1997; 126: 689-96.
26. Marriott DJ, Jones PD, Hoy JF, Speed BR, Harkness JL. Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. A double-blind placebo-controlled study. Med J Aust 1993; 158: 312-6.
27. Ellis ME, Clink H, Ernst P, Halim MA, Padmos A, Spence D, et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1994; 13: 3-11.
28. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study J Infect Dis 1995; 171: 1545-52.
29. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for haematological neoplasias. J Infect Dis 1995; 172: 1035-41.
30. Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukaemia. Results of a randomized placebo-controlled, double-blind, multicentre trial. Ann Intern Med 1993; 118: 495-503.
31. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-51.
32. Ruhnke M, Eigler A, Tennagen I, Geiseler B, Engelmann E, Trautmann M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994; 32: 2092-8.
33. Metzger S, Hofmann H. Fluconazole-resistant Candida species from HIV infected patients with recurrent Candida stomatitis: cross resistance to itraconazole and ketoconazole. Mycoses 1997; 40(Suppl 1): 56-63.
34. Chryssanthou E, Torssander J, Petrini B. Oral Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients. Scand J Infect Dis 1995; 27: 391-5.
35. Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B, et al. Candidaemia in cancer patients: a prospective, multicentre surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071-9.
36. Persons DA, Laughlin M, Tanner D, Perfect J, Gockerman JP, Hathorn JW. Fluconazole and Candida krusei fungaemia. N Engl J Med 1991; 325: 1315.
37. Chryssanthou E, Kalin M, Engervall P, Petrini B, Bjorkholm M. Low incidence of candidaemia among neutropenic patients treated for haematological diseases. Scand J Infect Dis 1998; 30: 489-93.